Matches in SemOpenAlex for { <https://semopenalex.org/work/W783851809> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W783851809 abstract "The new oral anticoagulant drugs include dabigatran (D), apixaban (A) and (R) rivaroxaban which have been recently approved for various indications. These agents produce their anticoagulant effects by inhibiting either Factor IIa or FXa. These drugs exhibit distinct pharmacologic profiles. Bleeding represents a major complication with the use of these agents. This study was designed to compare the bleeding profile of the agents in a standardized rat tail bleeding model. Powdered forms of active D, A and R were commercially obtained and a working solution was prepared at 100 ug/ml. Groups of rats were administered saline or each of the agents at 100 ug/kg IV. Bleeding measurements were made 5 minutes after the administration. Blood samples were drawn at the end of bleeding time for ex vivo analysis. In comparison to saline treated animals (300 + 60 sec), the D group exhibited a markedly high bleeding time (2250 + 240 sec), A did not show any significant increase (320 + 80 sec), whereas R exhibited a moderate increase (1110 + 130 sec). Ex vivo analysis of blood did not detect any D or R; however, varying levels of A were measurable. These studies show that at an equivalent dose of 100 ug/kg D produced a markedly stronger bleeding response, R produced a lowered response and A did not show any bleeding effect. Ex vivo results indicate that the stronger bleeding effects with D and R may relate to non-plasmatic mechanisms." @default.
- W783851809 created "2016-06-24" @default.
- W783851809 creator A5007859032 @default.
- W783851809 creator A5030457785 @default.
- W783851809 creator A5064983817 @default.
- W783851809 creator A5072266257 @default.
- W783851809 creator A5074304553 @default.
- W783851809 creator A5083350237 @default.
- W783851809 date "2013-04-01" @default.
- W783851809 modified "2023-09-23" @default.
- W783851809 title "Comparative hemmorhagic studies on dabigatran, apixaban and rivaroxaban in a rat‐tail bleeding model" @default.
- W783851809 doi "https://doi.org/10.1096/fasebj.27.1_supplement.lb505" @default.
- W783851809 hasPublicationYear "2013" @default.
- W783851809 type Work @default.
- W783851809 sameAs 783851809 @default.
- W783851809 citedByCount "0" @default.
- W783851809 crossrefType "journal-article" @default.
- W783851809 hasAuthorship W783851809A5007859032 @default.
- W783851809 hasAuthorship W783851809A5030457785 @default.
- W783851809 hasAuthorship W783851809A5064983817 @default.
- W783851809 hasAuthorship W783851809A5072266257 @default.
- W783851809 hasAuthorship W783851809A5074304553 @default.
- W783851809 hasAuthorship W783851809A5083350237 @default.
- W783851809 hasConcept C126322002 @default.
- W783851809 hasConcept C141071460 @default.
- W783851809 hasConcept C150903083 @default.
- W783851809 hasConcept C185592680 @default.
- W783851809 hasConcept C207001950 @default.
- W783851809 hasConcept C26291073 @default.
- W783851809 hasConcept C2776301958 @default.
- W783851809 hasConcept C2777397205 @default.
- W783851809 hasConcept C2778205648 @default.
- W783851809 hasConcept C2778661090 @default.
- W783851809 hasConcept C2778810321 @default.
- W783851809 hasConcept C2779161974 @default.
- W783851809 hasConcept C2779216453 @default.
- W783851809 hasConcept C2780638905 @default.
- W783851809 hasConcept C2993802102 @default.
- W783851809 hasConcept C3017811039 @default.
- W783851809 hasConcept C42219234 @default.
- W783851809 hasConcept C71924100 @default.
- W783851809 hasConcept C86803240 @default.
- W783851809 hasConcept C89560881 @default.
- W783851809 hasConcept C98274493 @default.
- W783851809 hasConceptScore W783851809C126322002 @default.
- W783851809 hasConceptScore W783851809C141071460 @default.
- W783851809 hasConceptScore W783851809C150903083 @default.
- W783851809 hasConceptScore W783851809C185592680 @default.
- W783851809 hasConceptScore W783851809C207001950 @default.
- W783851809 hasConceptScore W783851809C26291073 @default.
- W783851809 hasConceptScore W783851809C2776301958 @default.
- W783851809 hasConceptScore W783851809C2777397205 @default.
- W783851809 hasConceptScore W783851809C2778205648 @default.
- W783851809 hasConceptScore W783851809C2778661090 @default.
- W783851809 hasConceptScore W783851809C2778810321 @default.
- W783851809 hasConceptScore W783851809C2779161974 @default.
- W783851809 hasConceptScore W783851809C2779216453 @default.
- W783851809 hasConceptScore W783851809C2780638905 @default.
- W783851809 hasConceptScore W783851809C2993802102 @default.
- W783851809 hasConceptScore W783851809C3017811039 @default.
- W783851809 hasConceptScore W783851809C42219234 @default.
- W783851809 hasConceptScore W783851809C71924100 @default.
- W783851809 hasConceptScore W783851809C86803240 @default.
- W783851809 hasConceptScore W783851809C89560881 @default.
- W783851809 hasConceptScore W783851809C98274493 @default.
- W783851809 hasIssue "S1" @default.
- W783851809 hasLocation W7838518091 @default.
- W783851809 hasOpenAccess W783851809 @default.
- W783851809 hasPrimaryLocation W7838518091 @default.
- W783851809 hasRelatedWork W1973962795 @default.
- W783851809 hasRelatedWork W1996911008 @default.
- W783851809 hasRelatedWork W1997499869 @default.
- W783851809 hasRelatedWork W2136695943 @default.
- W783851809 hasRelatedWork W2181601210 @default.
- W783851809 hasRelatedWork W2288746335 @default.
- W783851809 hasRelatedWork W2603244127 @default.
- W783851809 hasRelatedWork W2766852435 @default.
- W783851809 hasRelatedWork W2908436399 @default.
- W783851809 hasRelatedWork W783851809 @default.
- W783851809 hasVolume "27" @default.
- W783851809 isParatext "false" @default.
- W783851809 isRetracted "false" @default.
- W783851809 magId "783851809" @default.
- W783851809 workType "article" @default.